Venturi Wealth Management LLC Trims Stock Holdings in Danaher Corporation (NYSE:DHR)

Venturi Wealth Management LLC trimmed its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 33.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,335 shares of the conglomerate's stock after selling 1,640 shares during the period. Venturi Wealth Management LLC's holdings in Danaher were worth $684,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of DHR. Fortis Capital Advisors LLC grew its holdings in Danaher by 1.3% in the 4th quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate's stock valued at $914,000 after buying an additional 50 shares in the last quarter. Fayez Sarofim & Co boosted its stake in shares of Danaher by 0.6% during the fourth quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock valued at $1,902,000 after purchasing an additional 50 shares in the last quarter. Coastal Bridge Advisors LLC raised its stake in shares of Danaher by 4.8% during the fourth quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock valued at $252,000 after acquiring an additional 50 shares during the last quarter. Perennial Investment Advisors LLC grew its position in shares of Danaher by 2.2% in the 4th quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate's stock valued at $538,000 after buying an additional 51 shares during the last quarter. Finally, MGO One Seven LLC raised its holdings in Danaher by 1.3% during the 4th quarter. MGO One Seven LLC now owns 4,285 shares of the conglomerate's stock worth $984,000 after purchasing an additional 53 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Insider Activity at Danaher

In other news, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the sale, the executive vice president directly owned 15,179 shares of the company's stock, valued at approximately $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Chairman Steven M. Rales sold 1,250,000 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the transaction, the chairman owned 3,105,808 shares of the company's stock, valued at $611,036,665.92. This represents a 28.70% decrease in their position. The disclosure for this sale can be found here. 11.10% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

DHR has been the subject of several research analyst reports. HSBC lowered their price objective on shares of Danaher from $270.00 to $240.00 in a research note on Friday, April 25th. Guggenheim reissued a "buy" rating and set a $250.00 price objective on shares of Danaher in a research report on Wednesday. Bank of America decreased their target price on Danaher from $265.00 to $230.00 in a research report on Monday, April 14th. Scotiabank upgraded Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective for the company in a report on Friday, July 11th. Finally, Leerink Partners upped their target price on Danaher from $225.00 to $230.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 23rd. Three research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $247.61.

Danaher Stock Up 1.4%

Shares of DHR stock traded up $2.79 during mid-day trading on Friday, reaching $205.60. 5,355,676 shares of the company's stock traded hands, compared to its average volume of 3,965,185. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $281.70. The company's 50-day moving average price is $196.38 and its 200-day moving average price is $203.92. The company has a market cap of $147.22 billion, a P/E ratio of 43.74, a P/E/G ratio of 2.82 and a beta of 0.77. The company has a quick ratio of 1.05, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%. The business had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. During the same period last year, the business posted $1.72 EPS. The company's revenue was up 3.4% compared to the same quarter last year. On average, equities analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, July 25th. Investors of record on Friday, June 27th were issued a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.62%. Danaher's dividend payout ratio is currently 27.23%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.